Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Caravan
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Reveal Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research seeks to improve a recently developed molecular MR probe (contrast agent) that will ultimately be used to detect fibrogenesis and monitor disease progression and drug treatment response in patients. Reveal Pharmaceuticals is developing non-gadolinium-based MRI contrast agents. The research and the company have an overlapping interest in the development of MRI contrast agents and, if the research is successful, the company may have an interest in the resulting IP.
Molecular MR Imaging of Hepatic Fibrogenesis
Project Narrative Fibrogenesis is active scarring of tissue that occurs in many chronic diseases (pulmonary fibrosis, chronic hepatitis, atrial fibrillation, hypertrophic cardiomyopathy, diabetic nephropathy). There are no methods to noninvasively detect and quantify fibrogenesis. We recently developed a magnetic resonance imaging (MRI) probe that can detect fibrogenesis and monitor disease progression and drug treatment response. The goal of this project is to improve this probe so that it is can be used in human patients.
Filed on August 06, 2019.
Tell us what you know about Peter Caravan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Peter Caravan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | $150,000 - $199,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | $20,000 - $39,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.